News & Media

Recent updates from Arcutis.

July 9, 2024 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

December 15, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

October 6, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

November 13, 2024

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

November 6, 2024

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

November 4, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 24, 2024

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

October 23, 2024

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

October 18, 2024

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

October 4, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 24, 2024

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

September 24, 2024

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

September 19, 2024

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

September 5, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 5, 2024

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download